Aerodose Insulin Inhaler Efficiency vs. Competition
Aerogen Henry et al Type 2 21%
2001 n=24
Sponsor Author/Date Patients Relative BA
Brunner et al Type 1 8%
Aradigm 2001
Novo Nordisk Kipnes et al Type 1 16%
2000 n=18
Inhale Skyler et al Type 1 5%
Pfizer/Aventis 2001 n=73
Previous slide
Next slide
Back to first slide
View graphic version